Mitochondrial dysfunction in AMI: mechanisms and therapeutic perspectives

Area of Science:

• Cardiovascular Research
• Mitochondrial Biology
• Immunology

Background:

• Acute myocardial infarction (AMI) and subsequent ischemia-reperfusion injury (MI/RI) are leading causes of mortality and disability worldwide.
• Percutaneous coronary intervention (PCI) is standard for AMI, but post-procedural MI/RI still causes significant cardiomyocyte damage and affects long-term prognosis.
• Mitochondrial dysfunction is increasingly identified as a key driver of cardiomyocyte death and inflammation in AMI.

Purpose of the Study:

• To review the complex mechanisms linking mitochondrial dysfunction to inflammation and immune dysregulation in AMI.
• To highlight the critical role of mitochondria in cardiomyocyte death following AMI and MI/RI.
• To explore emerging therapeutic strategies targeting mitochondria for AMI treatment.

Main Methods:

• Literature review focusing on the role of mitochondria in AMI pathophysiology.
• Analysis of signaling pathways involved in mitochondrial dysfunction and inflammation (e.g., cGAS, NLRs, TLRs).
• Examination of preclinical data for mitochondrial-targeted interventions.

Main Results:

• Mitochondria actively contribute to inflammation by activating signaling pathways like cGAS, NLRs, and TLRs.
• Mitochondrial dysfunction is a central mechanism in cardiomyocyte death and inflammatory responses post-AMI.
• Preclinical studies show efficacy for mitochondrial-targeted antioxidants, peptides, and transplantation.

Conclusions:

• Mitochondrial dysfunction plays a dual role in AMI, both causing and regulating inflammation.
• Targeting mitochondria offers a promising therapeutic avenue to mitigate MI/RI and improve outcomes in AMI patients.
• Further research into mitochondrial-based therapies is warranted for clinical translation.